Press Room

DDF - 15th American Drug Delivery & Formulation Summit

Start
Monday, September 15, 2025
End
Tuesday, September 16, 2025
Location: Boston, United States
Booth Number: Table #17



Hovione is exhibiting at the American Drug Delivery & Formulation Summit (DDF), an event that will once again bring together over 300 scientific leaders from pharma, biotech, and drug delivery industries. This edition features two days of presentations with an exceptional line-up of the industry's best speakers, including a Technology and Innovation Session led by Hovione experts.

Meet the Hovione team in Boston and don’t miss our Technology & Innovation Session

“Spray Drying of Biologics: Unlocking Full Potential through Formulation and Particle Engineering”

 

Spray drying is increasingly recognized as an enabling technology in drug product development, offering distinct advantages in particle engineering, stabilization, and enhancement of bioavailability. Although traditionally viewed as a challenging approach for biologics, recent advances in formulation science and process optimization have significantly broadened its applicability, paving the way for innovative formulation platforms across multiple delivery routes.

On September 15, in a session led by our R&D Director, João Pires, discover firsthand how spray drying has been successfully applied to develop robust and scalable biopharmaceutical formulation platforms.

Interested in knowing how we can ensure the stability and performance of your biologic drug product? Speak with our experts and learn how our extensive knowledge and experience can support your project from early stages of development to commercialization.

schedule a meeting

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026